Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Hormone therapy for prostate cancer
What hormone therapy for prostate cancer is, how androgen deprivation therapy starves cancer cells of testosterone, and what clinical evidence shows about survival and disease control. This guide outlines medication classes and surgical options, approximate costs in Turkey compared with the UK, US and Germany, expected side effects, recovery milestones and how to choose an accredited oncology centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Hormone Therapy for Prostate Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is hormone therapy for prostate cancer and how does it work?
Hormone therapy for prostate cancer, clinically referred to as androgen deprivation therapy (ADT), is a systemic treatment designed to suppress or block male hormones—primarily testosterone and dihydrotestosterone (DHT)—that stimulate the growth of prostate tumour cells. Prostate cancer cells rely on androgens binding to intracellular androgen receptors to multiply and survive. By lowering circulating testosterone to castration levels or blocking androgen receptors directly, hormone therapy slows tumour progression, shrinks existing lesions, and helps control the disease throughout the body. Oncology hospitals in Turkey provide comprehensive hormone protocols alongside other advanced oncology treatments in Turkey.
Hormone therapy is systemic, meaning it circulates through the bloodstream to target prostate cancer cells wherever they reside, whether confined to the prostate gland, spreading to regional lymph nodes, or metastasising to distant bones. Depending on the clinical stage, hormone therapy may be administered as neoadjuvant therapy before radiation, adjuvant therapy after primary treatment, or lifelong management for advanced metastatic disease. This clinical guide explains how androgen suppression works, what evidence supports its use, realistic costs across Turkey, the UK, US, and Germany, expected side effects, and practical guidance on planning treatment abroad.
Does hormone therapy for prostate cancer work? Clinical evidence and limits
Clinical trials and international oncology guidelines from bodies such as the European Association of Urology (EAU), National Institute for Health and Care Excellence (NICE), and American Urological Association (AUA) firmly establish that hormone therapy effectively reduces tumour burden and delays disease progression. In intermediate- and high-risk localised prostate cancer, combining hormone therapy with external beam radiotherapy significantly prolongs overall survival compared with radiation alone. For men with advanced or metastatic prostate cancer, starting androgen deprivation therapy promptly reduces serum prostate-specific antigen (PSA) levels, alleviates bone pain, and prevents urinary complications.
However, hormone therapy is not an independent cure for advanced prostate cancer. While it can suppress tumour activity for months or several years, most advanced tumours eventually adapt and resume growing despite low testosterone levels—a state known as castration-resistant prostate cancer (CRPC). When this transition occurs, oncologists do not discontinue therapy entirely; instead, they combine baseline hormone suppression with secondary agents, such as novel androgen receptor pathway inhibitors, specialised chemotherapy, or emerging cellular approaches such as immunotherapy. Clear clinical communication ensures patients understand that hormone therapy controls and stabilises prostate cancer rather than eradicating every dormant cell.
Hormone therapy for prostate cancer cost in Turkey compared with the UK, US and Germany
The financial commitment for hormone therapy varies depending on the specific pharmacological agents prescribed, the duration of the cycle, diagnostic imaging requirements, and whether treatment involves outpatient injections, oral tablets, or surgical castration. The cost of hormone therapy for prostate cancer in Turkey is generally lower than in Western Europe and North America due to differing operational overheads and regulated pharmaceutical pricing, while maintaining international standard medications.
The table below provides approximate cost ranges for an initial comprehensive oncological evaluation, staging scans (such as PSMA PET-CT), and an initial multi-month course of standard androgen deprivation therapy. These figures represent general estimates rather than fixed hospital quotations.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,500 – €4,500 |
| United Kingdom | €3,500 – €9,000 |
| United States | €6,000 – €18,000 |
| Germany | €3,000 – €8,500 |
Several key clinical variables influence the total hormone therapy for prostate cancer price. Standard luteinising hormone-releasing hormone (LHRH) agonist injections administered every one, three, or six months are relatively economical. In contrast, second-generation anti-androgen oral medications (such as enzalutamide, apalutamide, or abiraterone acetate) carry higher monthly manufacturing expenses. In Turkey, medical tourism oncology packages typically cover comprehensive baseline blood panels (total testosterone, complete PSA profile, liver and renal function), advanced staging imaging, the medical oncologist consultation, administration of the initial medication dose, and airport-hotel-clinic transfers. Ongoing prescription supplies for return travel are quoted transparently based on prescribed brand names and dosages.
Types of androgen deprivation therapy: injections, tablets and surgery
Modern urological oncology employs three primary strategies to achieve androgen suppression, each functioning through distinct pharmacological or physiological pathways:
- LHRH agonists (GnRH agonists): Medications such as leuprorelin (leuprolide), goserelin, and triptorelin initially overstimulate the pituitary gland, causing a temporary surge in testosterone known as a "flare", before downregulating receptors and reducing testosterone production to castration levels within two to four weeks. Anti-androgen tablets are typically prescribed for the first two weeks to counter this initial surge.
- LHRH antagonists (GnRH antagonists): Drugs such as degarelix (given as monthly subcutaneous injections) and relugolix (an oral daily tablet) block pituitary receptors immediately without inducing an initial testosterone spike, making them advantageous when rapid tumour suppression is needed to protect against spinal cord compression or severe urinary obstruction.
- Anti-androgens and novel receptor inhibitors: First-generation anti-androgens like bicalutamide block testosterone from binding to prostate cells. Newer second-generation agents, including enzalutamide, apalutamide, and darolutamide, provide deeper receptor blockade and are frequently combined with standard ADT in high-risk or metastatic disease.
- Surgical orchiectomy (bilateral subcapsular orchiectomy): A minor surgical procedure performed under local or general anaesthesia that removes the testosterone-producing tissue within the testicles. It permanently lowers testosterone levels within hours, eliminating the need for recurring depot injections.
Comparing androgen deprivation therapy with other prostate cancer modalities
Hormone therapy is rarely used in total isolation; it frequently forms the backbone of a comprehensive multidisciplinary strategy. Understanding how androgen deprivation aligns with complementary treatments helps patients navigate their broader care pathway. While hormone therapy reduces testosterone systemically, treatments like targeted therapy focus on specific molecular mutations within cancer cells, such as PARP inhibitors for BRCA-mutated tumours.
| Treatment modality | Best suited to | Typical limits |
|---|---|---|
| Hormone therapy (ADT) | Locally advanced tumours with radiation, recurring PSA, or metastatic disease | Controls rather than cures advanced disease; leads to hormone resistance over time |
| Systemic chemotherapy | Metastatic hormone-sensitive or castration-resistant prostate cancer | Greater haematological toxicity, hair thinning, and temporary immunosuppression |
| Targeted therapy | Tumours expressing specific genetic alterations (such as BRCA1/2 or ATM) | Requires prior genetic profiling; applicable only to specific molecular subgroups |
For localized high-risk tumours, combining hormone therapy for prostate cancer Turkey with external radiation therapy produces higher long-term disease-free survival than either modality used alone. Your oncology team will evaluate your Gleason score, tumour stage (TNM), and baseline imaging before recommending a single or multimodal approach.
Who is a candidate for hormone therapy for prostate cancer?
Determining whether hormone therapy is appropriate requires a rigorous assessment by a multidisciplinary tumour board. Medical oncologists recommend androgen suppression in several distinct clinical scenarios:
- Intermediate- and high-risk localised cancer: Given as neoadjuvant and adjuvant treatment for six months to three years alongside curative radiotherapy to improve local control and eradicate micro-metastases.
- Locally advanced prostate cancer: Tumours extending beyond the prostatic capsule (stage T3 or T4) where surgery alone carries a high probability of positive margins.
- Biochemical recurrence: Men who have previously undergone radical prostatectomy or radiation therapy and subsequently experience a rising PSA without visible distant metastases on standard scans.
- Metastatic prostate cancer: First-line foundational systemic treatment for men whose disease has spread to regional lymph nodes, visceral organs, or the skeletal system.
Conversely, hormone therapy is generally not recommended for men with low-risk, organ-confined prostate cancer where active surveillance, focal therapy, or localized surgery offers excellent outcomes without hormonal side effects. Additionally, patients with severe, unmanaged congestive heart failure or severe osteoporosis require thorough medical optimisation before initiating therapy, as androgen deprivation can exacerbate metabolic and cardiovascular vulnerabilities.
What does the treatment process involve step by step?
When undertaking hormone therapy abroad, structured coordination ensures medical safety, accurate dosing, and uninterrupted continuity of care upon returning home. The clinical pathway proceeds through five systematic stages:
- Step 1: Diagnostic re-evaluation and staging: Upon arrival in Turkey, the patient undergoes blood tests (total testosterone, free PSA, full blood count, metabolic panel, cardiac biomarkers) and modern imaging, most notably 68Ga-PSMA PET-CT, which provides precision mapping of prostate cancer cells throughout the body.
- Step 2: Multidisciplinary tumour board review: A team comprising medical oncologists, urologists, radiation oncologists, and radiologists reviews biopsy histology and scan findings to establish the optimal drug regimen and duration.
- Step 3: Cardiovascular and bone health assessment: Baseline dual-energy X-ray absorptiometry (DEXA) scans assess bone mineral density, while an electrocardiogram (ECG) and cardiology review evaluate cardiovascular status before medication starts.
- Step 4: Initial drug administration: The patient receives their first deep intramuscular or subcutaneous depot injection (effective for one, three, or six months) or begins their oral medication protocol under nursing supervision. If surgical orchiectomy is selected, the minor outpatient operation is performed under local or light general anaesthesia.
- Step 5: Post-administration monitoring and discharge: The medical team monitors the patient for immediate adverse reactions, issues an extensive medical dossier in English, provides a supply of oral medications or injection documentation, and coordinates a monitoring plan for the patient's home physician.
Hormone therapy for prostate cancer recovery and side effect management
Because hormone therapy is a pharmacological rather than invasive surgical intervention, physical recovery from the injection itself is immediate, with only mild tenderness at the injection site. However, systemic adaptation to suppressed testosterone represents an ongoing journey. Understanding expected physiological changes helps patients maintain vitality and functional independence throughout treatment.
Common physiological effects of androgen deprivation include hot flushes, mild fatigue, decreased libido, erectile dysfunction, gradual loss of lean muscle mass, and mild weight gain around the abdomen. Emotional fluctuations, mood changes, and reduced stamina can also occur. International oncology centres provide comprehensive supportive care plans that include dietary counselling, targeted exercise prescriptions, and bone-strengthening supplements (calcium and vitamin D). Resistance training twice weekly has been proven in clinical studies to counteract muscle loss, preserve bone density, and mitigate cancer-related fatigue.
For international patients, travel logistics are straightforward. Most men spend three to five days in Turkey for their initial staging workup, oncologist consultation, and initial injection administration. Once the medical team verifies tolerance, patients are fully fit to fly home. Routine blood tests and subsequent depot injections can easily be administered by a local general practitioner or oncologist using the formal treatment plan provided by the Turkish hospital.
Risks, long-term health effects and clinical monitoring
Prolonged androgen deprivation influences several organ systems, requiring proactive monitoring and preventive lifestyle modifications. Reputable oncology bodies, including the NHS, ESMO, and the American Heart Association, highlight several long-term health considerations:
- Bone mineral density loss: Lower testosterone levels accelerate bone turnover, increasing the risk of osteopenia and fractures over long-term therapy. Baseline and periodic DEXA scans are essential; bisphosphonates or denosumab may be prescribed to protect skeletal integrity.
- Cardiovascular and metabolic changes: Suppression of testosterone alters lipid profiles, increases insulin resistance, and can lead to elevated blood glucose and blood pressure. Patients with pre-existing heart conditions require close collaboration between oncologists and cardiologists.
- Anaemia and fatigue: Testosterone stimulates red blood cell production in bone marrow; suppression can cause mild normocytic anaemia, contributing to lethargy.
- Cognitive and emotional health: Some men report subtle changes in short-term memory, mental processing speed, or depressive symptoms. Supportive psychological care and social support networks play an important role during active treatment.
Routine clinical surveillance requires testing total serum testosterone and PSA every three to six months to confirm that testosterone remains at castrate levels (typically under 50 ng/dL or 1.7 nmol/L) and that PSA remains suppressed. Any sustained rise in PSA warrants repeat imaging to detect early secondary resistance.
How to choose an oncology hospital in Turkey and red flags to avoid
Selecting an oncology provider for prostate cancer care requires thorough verification of clinical standards, equipment, and medical credentials. Prioritise hospitals accredited by Joint Commission International (JCI) or certified by the Turkish Ministry of Health for medical tourism. Ensure the facility features an established multidisciplinary uro-oncology tumour board, access to advanced diagnostic imaging such as 68Ga-PSMA PET-CT, and certified medical oncologists experienced in the latest international treatment protocols.
Be alert to significant red flags when evaluating prospective clinics:
- Clinics that promise an absolute or permanent cure for advanced or metastatic prostate cancer using hormone therapy alone.
- Facilities offering hormone medications without requiring formal histological biopsy confirmation, PSA records, or recent staging imaging.
- Unwillingness to provide the exact pharmaceutical brand name, manufacturer details, and dosage specifications in writing prior to administration.
- Absence of a documented post-treatment transition plan for your local healthcare provider once you return home.
- High-pressure sales representatives demanding immediate financial deposits before a qualified oncologist has evaluated your medical history.
To understand the complete international patient journey, read about how it works and submit your diagnostic records through our free quote portal to receive a detailed clinical proposal and transparent estimate from a certified oncology hospital.
Essential questions to ask your medical oncology team
Before initiating hormone therapy, preparing focused questions empowers you to make well-informed decisions regarding your oncological care. Consider discussing the following points during your initial consultation:
- What specific type of hormone therapy (agonist, antagonist, or anti-androgen) is most appropriate for my prostate cancer stage, and why?
- What is the planned duration of my hormone therapy—is it a defined adjuvant course or long-term management?
- Will I receive an anti-androgen tablet beforehand to prevent an initial testosterone flare?
- What baseline assessments (cardiac review, DEXA bone scan, PSA, testosterone) will be completed before my first injection?
- What specific lifestyle interventions, exercise programmes, or dietary changes do you recommend to minimise muscle loss and fatigue?
- How will my treatment plan be coordinated with my domestic doctor or oncologist after I return home?
- What symptoms or warning signs should prompt immediate medical evaluation while I am abroad and once I return home?
Hospitals with Oncology in Turkey
Frequently asked questions
Hormone therapy for prostate cancer, or androgen deprivation therapy, is a medical treatment that lowers male hormone levels or blocks them from reaching cancer cells. Because prostate cancer cells depend on testosterone to multiply, suppressing these hormones slows tumour growth, shrinks lesions, and helps control the disease throughout the body.
Yes, clinical trials demonstrate that hormone therapy reliably reduces PSA levels and shrinks tumours. In intermediate- and high-risk localised disease, combining it with radiation therapy significantly prolongs survival. In metastatic disease, it slows progression and eases symptoms, although advanced cancer can eventually develop resistance, requiring oncologists to introduce secondary systemic therapies.
Initial evaluation, PSMA PET-CT staging, oncologist consultations, and an initial depot injection course in Turkey generally range between €1,500 and €4,500, compared with €3,500 to €9,000 in the UK. The exact cost depends on the specific drug class prescribed, treatment duration, and whether additional oral anti-androgens are required.
Before starting therapy, men often experience elevated PSA levels and sometimes urinary or skeletal symptoms. After beginning treatment, PSA typically drops substantially within weeks, and imaging reveals tumour shrinkage. However, patients must prepare for physical changes, including hot flushes, fatigue, and gradual muscle loss, which can be managed with structured resistance exercise and dietary adjustments.
Physical recovery from the injection itself is immediate, with normal daily routines resumed on the same day. Managing ongoing physiological side effects, such as reduced energy, hot flushes, and metabolic changes, is an ongoing process. Oncologists advise twice-weekly strength training, balanced nutrition, and vitamin D supplementation to maintain muscle mass and bone strength throughout active treatment.
The depot injections cause only momentary discomfort similar to a standard vaccination or blood test. Mild soreness or redness at the injection site typically subsides within 24 to 48 hours. The medication itself does not cause pain, and for men with painful bone metastases, lowering testosterone frequently provides significant pain relief.
Duration varies according to disease risk and stage. For localized high-risk prostate cancer treated with radiation, hormone therapy typically continues for six months to three years. In metastatic disease, hormone suppression is usually continued indefinitely to keep cancer cells dormant, transitioning to novel combination therapies if the disease eventually stops responding to initial drugs.
Hormone therapy has been widely studied and safely administered for decades. While safe, lowering testosterone affects metabolic health, bone density, and cardiovascular function over time. Clinical guidelines recommend regular monitoring of blood glucose, cholesterol, bone density, and cardiac status so preventive measures can be introduced promptly if health markers change.
Hormone therapy controls prostate cancer by depriving cells of androgen stimulation, usually causing fewer haematological side effects. Chemotherapy uses cytotoxic drugs like docetaxel to destroy rapidly dividing cells directly. While hormone therapy is standard first-line systemic care, chemotherapy is typically introduced alongside hormone therapy in aggressive metastatic disease or when castration resistance develops.
Most patients stay three to five days in Turkey. This window provides ample time for comprehensive blood panels, PSMA PET-CT scanning, multidisciplinary tumour board review, and initial medication administration. After a post-treatment check and receiving a full medical dossier with prescriptions, patients safely fly home to continue follow-up locally.
Patient stories